148 related articles for article (PubMed ID: 33806019)
1. Targeting the IL-6/STAT3 Signalling Cascade to Reverse Tamoxifen Resistance in Estrogen Receptor Positive Breast Cancer.
Tsoi H; Man EPS; Chau KM; Khoo US
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33806019
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer.
Tsoi H; Shi L; Leung MH; Man EPS; So ZQ; Chan WL; Khoo US
Life (Basel); 2022 Jan; 12(1):. PubMed ID: 35054486
[TBL] [Abstract][Full Text] [Related]
3. BQ323636.1, a Novel Splice Variant to
Gong C; Man EPS; Tsoi H; Lee TKW; Lee P; Ma ST; Wong LS; Luk MY; Rakha EA; Green AR; Ellis IO; Lam EW; Cheung KL; Khoo US
Clin Cancer Res; 2018 Aug; 24(15):3681-3691. PubMed ID: 29420220
[No Abstract] [Full Text] [Related]
4. Checkpoint Kinase 2 Inhibition Can Reverse Tamoxifen Resistance in ER-Positive Breast Cancer.
Tsoi H; Tsang WC; Man EPS; Leung MH; You CP; Chan SY; Chan WL; Khoo US
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293165
[TBL] [Abstract][Full Text] [Related]
5. SpliceArray profiling of breast cancer reveals a novel variant of NCOR2/SMRT that is associated with tamoxifen resistance and control of ERα transcriptional activity.
Zhang L; Gong C; Lau SL; Yang N; Wong OG; Cheung AN; Tsang JW; Chan KY; Khoo US
Cancer Res; 2013 Jan; 73(1):246-55. PubMed ID: 23117886
[TBL] [Abstract][Full Text] [Related]
6. SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer.
Tsoi H; Fung NN; Man EPS; Leung MH; You CP; Chan WL; Chan SY; Khoo US
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190199
[TBL] [Abstract][Full Text] [Related]
7. A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2.
Leung MH; Tsoi H; Gong C; Man EP; Zona S; Yao S; Lam EW; Khoo US
Cancers (Basel); 2020 Feb; 12(3):. PubMed ID: 32110852
[TBL] [Abstract][Full Text] [Related]
8. SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL-6/STAT3 signal pathway.
Xing J; Li J; Fu L; Gai J; Guan J; Li Q
Cancer Med; 2019 Nov; 8(16):7086-7097. PubMed ID: 31573734
[TBL] [Abstract][Full Text] [Related]
9. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
10. IL-33 facilitates endocrine resistance of breast cancer by inducing cancer stem cell properties.
Hu H; Sun J; Wang C; Bu X; Liu X; Mao Y; Wang H
Biochem Biophys Res Commun; 2017 Apr; 485(3):643-650. PubMed ID: 28216163
[TBL] [Abstract][Full Text] [Related]
11. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
12. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
13. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
14. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
Chong K; Subramanian A; Sharma A; Mokbel K
Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576
[TBL] [Abstract][Full Text] [Related]
15. Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.
Cutrupi S; Reineri S; Panetto A; Grosso E; Caizzi L; Ricci L; Friard O; Agati S; Scatolini M; Chiorino G; Lykkesfeldt AE; De Bortoli M
Oncogene; 2012 Oct; 31(40):4353-61. PubMed ID: 22249258
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.
Jansen MP; Sas L; Sieuwerts AM; Van Cauwenberghe C; Ramirez-Ardila D; Look M; Ruigrok-Ritstier K; Finetti P; Bertucci F; Timmermans MM; van Deurzen CH; Martens JW; Simon I; Roepman P; Linn SC; van Dam P; Kok M; Lardon F; Vermeulen PB; Foekens JA; Dirix L; Berns EM; Van Laere S
Mol Oncol; 2015 Jun; 9(6):1218-33. PubMed ID: 25771305
[TBL] [Abstract][Full Text] [Related]
18. Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.
Busch S; Sims AH; Stål O; Fernö M; Landberg G
Cancer Res; 2015 Apr; 75(7):1457-69. PubMed ID: 25833830
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
20. Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells.
Pulliam N; Tang J; Wang W; Fang F; Sood R; O'Hagan HM; Miller KD; Clarke R; Nephew KP
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30621214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
